Given that co-occurrence of SPOP mutations and CHD1 deletion define a distinct molecular subtype of prostate cancer, further studies are needed to assess if they have synergistic effects in response to DNA-damaging therapies. This evidence concerns the gene CHD1 and prostate cancer.